BiotechTube

Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion Injection

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sedation in the ICU

Conditions

Sedation in the ICU

Trial Timeline

Mar 12, 2024 → Sep 24, 2024

NCT ID
NCT06222294

About Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion Injection

Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion Injection is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Sedation in the ICU. The current trial status is completed. This product is registered under clinical trial identifier NCT06222294. Target conditions include Sedation in the ICU.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06222294Phase 3Completed

Competing Products

20 competing products in Sedation in the ICU

See all competitors
ProductCompanyStageHype Score
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCIEisaiPhase 3
77
Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + FentanylEisaiApproved
85
fospropofol disodium Subgroup 1 Lower Dose + fospropofol disodium Subgroup 1 Approved Dose + fospropofol disodium Subgroup 2 Lower Dose + fospropofol disodium Subgroup 2 Approved Dose + fospropofol disodium Subgroup 3 Lower Dose + fospropofol disodium Subgroup 3 Approved DoseEisaiApproved
85
AQUAVAN® (fospropofol disodium) InjectionEisaiPhase 2/3
65
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
52
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
77
Remimazolam TosilateJiangsu Hengrui MedicineApproved
85
Remimazolam TosilateJiangsu Hengrui MedicinePhase 1/2
41
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
23
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
77
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
77
SHR0302 Base Gel + SHR0302 Base Gel PlaceboJiangsu Hengrui MedicinePhase 1
33
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
23
Remimazolam Tosilate for Injection + Remimazolam Tosilate for InjectionJiangsu Hengrui MedicineApproved
85
Remimazolam Tosilate for injection + Propofol InjectionJiangsu Hengrui MedicinePhase 2/3
65
Dexmedetomidine hydrochloride nasal spray + Dexmedetomidine hydrochloride nasal spray blank preparation.Jiangsu Hengrui MedicinePhase 1
33
Intranasal Dexmedetomidine + Intravenous Dexmedetomidine + Intranasal Placebo + Intravenous PlaceboJiangsu Hengrui MedicinePhase 1
33
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 2
52
dexmedetomidine nasal spray + dexmedetomidine hydrochloride nasal spray blank preparationJiangsu Hengrui MedicinePhase 2/3
65
Remimazolam Tosilate + Propofol Injection.Jiangsu Hengrui MedicinePhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85